Journal: Nanoscale Advances

Article Title: Continuously manufactured single-core iron oxide nanoparticles for cancer theranostics as valuable contribution in translational research

doi: 10.1039/d0na00343c

Figure Lengend Snippet: Determination of cell viability of brain microvascular endothelial cells (hCMEC) after treatment with MNP samples (exemplarily T1). Cells were seeded on 96-well plates and treated with several concentrations of nanoparticles for various time periods. Cells were washed and thereafter incubated with a CCK-8 substrate. After 60 minutes, the absorbance was measured at λ = 450 nm. Untreated cells (Ctrl) were set to 100% viability. No cytotoxic effects were observed neither short term (4 h) (top) nor long-term up to 72 h (bottom).

Article Snippet: Immortalized human cerebral microvascular endothelial cells (hCMEC/D3; Biozol) were maintained in rat tail collagen-I (50 μg mL −1 ; Ibidi GmbH) -coated culture flasks in ECBM MV cell culture media (PromoCell) supplemented with 15% fetal bovine serum (FBS), 2.5 ng mL −1 basal fibroblast growth factor, 10 μg mL −1 sodium heparin (all Sigma-Aldrich).

Techniques: Incubation, CCK-8 Assay

Journal: Nanoscale Advances

Article Title: Continuously manufactured single-core iron oxide nanoparticles for cancer theranostics as valuable contribution in translational research

doi: 10.1039/d0na00343c

Figure Lengend Snippet: Determination of cell death and apoptosis of brain microvascular endothelial cells after treatment with MNPs for 24 h (top) and 72 h (bottom). Cells were analyzed by flow cytometry after staining with annexin-V-FITC and propidium iodide. Cell populations in percent of total cells have been blotted. One-way ANOVA followed by Tukey's multiple comparisons test was performed. The data of each group (living, dead, and apoptotic) were statistically evaluated separately from each other ( n = 3–4).

Article Snippet: Immortalized human cerebral microvascular endothelial cells (hCMEC/D3; Biozol) were maintained in rat tail collagen-I (50 μg mL −1 ; Ibidi GmbH) -coated culture flasks in ECBM MV cell culture media (PromoCell) supplemented with 15% fetal bovine serum (FBS), 2.5 ng mL −1 basal fibroblast growth factor, 10 μg mL −1 sodium heparin (all Sigma-Aldrich).

Techniques: Flow Cytometry, Staining

Journal: Diabetologia

Article Title: Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

doi: 10.1007/s00125-019-4918-x

Figure Lengend Snippet: GLP-1R inhibition does not alter the skin microvascular response to liraglutide in healthy individuals. Each participant ( n =15) had 4 treatment sites, each receiving two microinjections: saline site (saline followed by saline); exendin-(9,39) (exendin-(9,39) followed by saline); liraglutide (saline followed by liraglutide); exendin-(9,39) liraglutide (exendin-(9, 39) followed by liraglutide). ( a ) Stabilised response, data presented as median (25th–75th percentile). ( b ) Total response, data presented as mean (SD). The skin perfusion response at the saline site was significantly lower than the response (stabilised and total) at the liraglutide site (** p <0.01 by Wilcoxon signed rank test for stabilised response; by paired t test for total response). Pretreatment by microinjection of exendin-(9,39) did not alter the microvascular response to liraglutide (liraglutide site vs exendin-9,39 liraglutide site, p ≥0.609 by Wilcoxon signed rank test for stabilised response; by paired t test for total response)

Article Snippet: The role of NO in mediating the microvascular actions of GLP-1 analogues was examined in cultured human microvascular endothelial cells (HCMEC/D3 cell line) [ ] by assessing the effects of exenatide (100 pmol/l) (Isca Biochemicals, Exeter, UK) and liraglutide (10 nmol/l) (Isca Biochemicals) on endothelial nitric oxide synthase (eNOS) activation (phosphorylation) and nitrate levels.

Techniques: Inhibition, Saline, Microinjection

Journal: Diabetologia

Article Title: Locally delivered GLP-1 analogues liraglutide and exenatide enhance microvascular perfusion in individuals with and without type 2 diabetes

doi: 10.1007/s00125-019-4918-x

Figure Lengend Snippet: Exenatide and liraglutide increase eNOS phosphorylation and nitrate levels. ( a ) eNOS phosphorylation: after initial starvation, human microvascular endothelial cells (HCMEC/D3s) were treated with exenatide and liraglutide for 10 min. Controls were treated with 0.1% BSA medium only. Phosphorylation data were normalised to total eNOS ( n =8). ( b ) Nitrate levels: HCMEC/D3s were treated with exenatide and liraglutide for 24 h ( n =9). Controls were treated with medium only. For both ( a ) and ( b ), data are expressed as percentage of control, with control set at 100%, and are presented as median (25th–75th percentile). * p <0.05, ** p <0.01 vs control, Wilcoxon sign rank test.

Article Snippet: The role of NO in mediating the microvascular actions of GLP-1 analogues was examined in cultured human microvascular endothelial cells (HCMEC/D3 cell line) [ ] by assessing the effects of exenatide (100 pmol/l) (Isca Biochemicals, Exeter, UK) and liraglutide (10 nmol/l) (Isca Biochemicals) on endothelial nitric oxide synthase (eNOS) activation (phosphorylation) and nitrate levels.

Techniques: Phospho-proteomics, Control